ArticleJournal of translational medicine2012

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

Consolación Melguizo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.